La Jolla Pharmaceutical Company (NASDAQ:LJPC)‘s stock had its “buy” rating reaffirmed by analysts at Jefferies Group LLC in a note issued to investors on Tuesday. They currently have a $40.00 price target on the biopharmaceutical company’s stock. Jefferies Group LLC’s price objective would suggest a potential upside of 15.56% from the stock’s current price.

Several other research firms also recently commented on LJPC. Zacks Investment Research downgraded La Jolla Pharmaceutical from a “buy” rating to a “hold” rating in a report on Tuesday, July 18th. BidaskClub upgraded La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a report on Wednesday, August 9th. Chardan Capital restated a “buy” rating and set a $85.00 target price on shares of La Jolla Pharmaceutical in a report on Tuesday, August 8th. Finally, J P Morgan Chase & Co initiated coverage on La Jolla Pharmaceutical in a research report on Wednesday, August 30th. They set an “overweight” rating and a $36.00 price target on the stock. Three analysts have rated the stock with a hold rating and six have given a buy rating to the stock. La Jolla Pharmaceutical currently has a consensus rating of “Buy” and an average price target of $51.00.

Shares of La Jolla Pharmaceutical (LJPC) traded down 3.418% during midday trading on Tuesday, hitting $34.615. The stock had a trading volume of 294,805 shares. The stock’s market cap is $765.79 million. La Jolla Pharmaceutical has a 1-year low of $14.63 and a 1-year high of $39.28. The firm’s 50-day moving average price is $32.47 and its 200-day moving average price is $30.74.

La Jolla Pharmaceutical (NASDAQ:LJPC) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.09). During the same quarter last year, the firm posted ($0.90) EPS. Analysts forecast that La Jolla Pharmaceutical will post ($4.99) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Jefferies Group LLC Reiterates Buy Rating for La Jolla Pharmaceutical Company (LJPC)” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/03/jefferies-group-llc-reiterates-buy-rating-for-la-jolla-pharmaceutical-company-ljpc.html.

Several large investors have recently modified their holdings of the company. Legal & General Group Plc boosted its holdings in shares of La Jolla Pharmaceutical by 11.6% during the second quarter. Legal & General Group Plc now owns 4,456 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 462 shares during the period. SG Americas Securities LLC purchased a new position in La Jolla Pharmaceutical during the 1st quarter valued at about $195,000. Voya Investment Management LLC purchased a new position in La Jolla Pharmaceutical during the 2nd quarter valued at about $243,000. American International Group Inc. increased its holdings in La Jolla Pharmaceutical by 7.1% during the 1st quarter. American International Group Inc. now owns 8,571 shares of the biopharmaceutical company’s stock valued at $256,000 after purchasing an additional 568 shares during the period. Finally, State Board of Administration of Florida Retirement System purchased a new position in La Jolla Pharmaceutical during the 1st quarter valued at about $271,000.

About La Jolla Pharmaceutical

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).

Analyst Recommendations for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Stock Ratings for La Jolla Pharmaceutical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical Company and related stocks with our FREE daily email newsletter.